Clinical trials
catalyst calendar across sponsors →Studies where TRDA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional · 1 observational
Held by 8 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, AQR CAPITAL MANAGEMENT LLC, CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, Qube Research & Technologies Ltd, +3 more) · FINRA short interest 4.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)NCT07682129Number of participants with Treatment Emergent Adverse Events (TEAEs) according to study protocol (Part A and OL Period)Non-randomized · Open-label · Treatment | Phase 2 | Not yet recruiting | Drug: ENTR-601-44, ENTR-601-45 | Duchenne Muscular Dystrophy (DMD) | 80 | Mar 2032 | ≤ 2,051 d | 2026-07-02 |
| A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44NCT07037862Number of participants with Treatment Emergent Adverse Events (TEAEs) according to study protocol (Part A and Open Label (OL) Period)Randomized · Quadruple-masked · Treatment | Phase 1/2 | Recruiting | Drug: ENTR-601-44, ENTR-601-44 - matching placebo | Duchenne Muscular Dystrophy (DMD) | 24 | 2029-03-28 | in 952 d | 2026-08-13 |
| A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45NCT07038824Number of participants with Treatment Emergent Adverse Events (TEAEs) according to study protocol (Part A and OL Period).Randomized · Quadruple-masked · Treatment | Phase 1/2 | Recruiting | Drug: ENTR-601-45, ENTR-601-45 - matching placebo | Duchenne Muscular Dystrophy (DMD) | 24 | 2029-03-01 | in 925 d | 2026-08-13 |
| Natural History Study of MNGIENCT04245917observationalMNGIE Clinical Course | — | Suspendedsponsor's stated reason: Business Reason | Other: Non-interventional | Mitochondrial Neurogastrointestinal Encephalomyopathy | 60 | Feb 2025 | — | 2021-07-22 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19